New Task Order Request for Proposal Solicitation for PREVENT R&D Project Titled "Chemopreventive Potential of a Urolithin A Derivative in a Mouse Model of Tobacco Carcinogen-Induced Lung Adenocarcinoma"
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $700,000 to $1,500,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Points of contact
-
- Rachel Turk rachel.turk@nih.gov
- John Clifford john.clifford@nih.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health is issuing a new-requirement task order request for proposal for the PREVENT R&D project "Chemopreventive Potential of a Urolithin A Derivative in a Mouse Model of Tobacco Carcinogen-Induced Lung Adenocarcinoma," with an estimated solicitation release date of June 1, 2026 and an estimated award date of September 1, 2026. The task order will systematically evaluate the cancer preventive effectiveness and safety of mitochondria-targeted urolithin A (Mito-UA) across early through late stages of lung cancer development in a tobacco carcinogen-induced lung tumor model. It extends prior animal studies that showed Mito-UA suppresses lung cancer development and progression, generating data for patient trials of lung cancer prevention in smokers and former smokers.
The estimated award value range is $700,000 to $1.5 million under NAICS 541714, Research and Development in Biotechnology (except Nanobiotechnology), with no set-aside used. Points of contact are Rachel Turk (rachel.turk@nih.gov) and John Clifford (john.clifford@nih.gov), both at NIH.
Forecast text
Lung cancer is the top cause of cancer deaths in the US. Most cases are due to smoking, and the cancer rates among former smokers are rising. There are currently no approved treatments for the prevention of lung cancer. The goal of this task order is to systematically evaluate the cancer preventive effectiveness and safety of a novel drug, mitochondria-targeted urolithin A (Mito-UA). The drug will be tested across different stages of lung cancer development, from very early to late stage, using a tobacco carcinogen-induced lung tumor model. In previous, initial studies Mito-UA has been shown to suppress lung cancer development and progression in several animal models. This task order is aimed at extending and expanding those studies to in order to provide the data necessary for its use in patient trials for preventing lung cancer amongst smokers and former smokers. Should this task order not be funded, the testing of Mito-UA for lung cancer prevention in a clinical trial would not be possible.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast